Author: admin

 

The New York Times has made the astounding revelation that not a single athlete or visitor got infected by the Zika virus in the recently concluded Rio Olympics. The Times quotes health specialists from the WHO, who of course do not provide any reliable piece of evidence as to how they came to the conclusion that no one has the Zika virus incubating inside him or her without the benefit of serological or PCR molecular tests. For al we know dozens or even hundreds must have got infected keeping in mind that almost 80% of people infected by the Zika virus do not show any symptoms but are quite capable of transmitting the disease.

Continue reading “CHIKUNGUNYA SHOULD NOT BE UNDERESTIMATED.”

 

 

Beta-blockers are the foundation of drug treatment for patients of angina. The COURAGE trial convincingly confirmed the fact that medical therapy was equivalent to percutaneous coronary intervention (PCI) in patients with stable angina. The rates of death and myocardial infarction did not differ in both groups; this was a randomized study. Medical therapy almost always consisted of a beta-blocker with addition of a calcium blocker and nitrates. Beta-blockers are successful in treatment of stable angina by their ability of reducing myocardial oxygen consumption.

 

Continue reading “BETA-BLOCKERS ARE INEFFECTIVE IN PATIENTS WITH STABLE ANGINA WHO HAVE UNDERGONE PCI”

 

 

 

 

Recently an elegant research paper (JACC 2016;68(7)727-38) has reported clinical outcomes and cardiac magnetic resonance imaging (CMR) in patients with and without diabetes randomized randomized to intracoronary (IC) or intravenous bolus injection of abciximab at the time of primary percutaneous coronary intervention (PPCI). Continue reading “INTRACORONARY ABCIXIMAB BOLUS IN DIABETIC PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION.”

 

 

 

Great emphasis has been laid upon the SYNTAX Score (SS) for stratifying patients for coronary intervention. All cardiology societies unanimously agree that an SS of >22 merits coronary bypass surgery (CABG) as opposed to percutaneous coronary intervention (PCI) with a drug eluting stent (DES). This conclusion has been drawn from the SYNTAX Trial published in 2009. This was the largest randomized trial conducted that compared CABG to PCI in patients of coronary artery disease. About two thirds patients had stable angina while the remaining suffered from unstable angina. It was necessary that there was 50% diameter stenosis of a concerned artery and the smallest vessel taken into account was at least 1.5 mm in diameter.

Continue reading “IS THE SYNTAX SCORE OBSOLETE WHEN DECIDING ON PCI IN PATIENTS WITH LEFT MAIN DISEASE ??”

 

A recent report in JACC (2016;68:450) provides the stunning realisation that of more than 67,000 patients admitted with heart failure in the USA, less than half a percent of patients underwent stress echocardiography to pick up coronary artery disease (CAD) as the underlying cause despite the fact that 50% to 60% of heart failure patients have CAD as the underlying triggering factor. Astoundingly more than 80% of patients did not undergo any form of testing for ischemic heart disease. Continue reading “GROSS UNDER-UTILISATION OF TESTS TO DETECT ISCHEMIC HEART DISEASE IN HEART FAILURE PATIENTS.”

 

 

It is well known that diabetes is associated with cognition impairment (CI). Recent studies have recorded a link between diabetes and mild cognitive impairment in parsons of earlier onset and greater severity of diabetes. There is evidence that lack of glycemic control resulting in hypo- or hyperglycemia leads to CI in patients with diabetes. Cognition impairment can present as changes in memory, mood swings, perception, reaction times and concentration. While the association between CI (and dementia) and diabetes is clear, researchers do not fully understand the mechanism of how diabetes triggers dementia.

Continue reading “THE FIRST WORLD LEADER FROM THE WEST TO HAVE TYPE 1.5 DIABETES.”

 

 

 

Fibromuscular dysplasia (FMD) is a non-inflammatory disease that manifests as stenosis, dissection, aneurysm, beading or tortuosity. The disease affects mainly women between 30 and 60 years but can affect both sexes and all ages. A rough estimate of prevalence has been estimated from kidneys donated for renal transplant. It was first described in 1938 in a 5- year old boy with hypertension due to unilateral renal artery involvement. It took another 30 years to realize that arteries other than renal could also be involved. In 1964, coeliac, superior mesenteric, splenic and external iliac arteries were found to be involved with FMD.

Continue reading “FIBROMUSCULAR DYSPLASIA AND CORONARY ARTERY DISSECTION”

 

 

Transcatheter aortic valve replacement (TAVR), performed for the first time in 2002, is now considered a suitable alternative to surgical valve replacement (SAVR) in high-risk patients with severe symptomatic aortic stenosis. The PARTNER trial was the first to directly compare TAVR to SAVR head to head in high surgical risk patients; at 1 year TAVR performed with balloon expandable Edwards-Sapien valve was non- inferior to SAVR (24% vs. 27%). This was maintained at 5 years follow up (68% vs. 62%).

Continue reading “TRANSCATHETER AORTIC VALVE REPLACEMENT FOR INTERMEDIATE AND HIGH RISK PATIENTS WITH SEVERE AORTIC STENOSIS”

 

There are currently millions of patients with diabetes in India, which is rapidly becoming the world’s capital for diabetes largely due to the horrendous life styles adopted by the general population. India is home to more than 60 million diabetics (95% are people with Type 2 diabetes).There will be more than a 100 million by the year 2030. Almost 2.1% of the Indian GDP is spent in treating diabetes and its complications, including myocardial infarction, heart failure, stroke, blindness, kidney failure and amputation. The average Indian loves his or her food and the only exercise done is sitting up watching a game of cricket on TV.

Continue reading “THE “NEW ERA” IN THE TREATMENT OF TYPE 2 DIABETES, WITH INJECTION LIRAGLUTIDE.”

 

 

 

 

 

Thoracic aortic aneurysm (TAA) is associated with the extreme complication of acute aortic dissection (AOD). People with genetically associated TAA are at greater risk of AOD due to structural alterations in their aorta. Marfan Syndrome (MFS), bicuspid aortic valve (BAV), Ehlers-Danlos syndrome, Loeys-Dietz syndrome, Turner syndrome, and familial TAA are the usual causes of genetic TAA, and of these MFS and BAV are the commonest.

Continue reading “PREDICTING ACUTE AORTIC DISSECTION IN GENETIC AORTOPATHY.”

 

 

The latest issue of JACC (2016;67:2593-603) reports a randomized study that assesses the efficacy and safety of high dose vitamin D (D) in patients with chronic systolic heart failure (HF) accompanied with deficiency in vitamin D. 229 patients of HF and low D (< 20 ng/ml) were provided 100 mcg or 4000 units of 25(OH) vitamin D3 (cholecalciferol) supplementation. The primary endpoint was 6 minute walking distance and secondary endpoints were change in left ventricle ejection fraction (LVEF) at one year. Safety measures of renal function and serum calcium concentration were measured every 3 months.

Continue reading “VITAMIN D 3 CAN INCREASE LEFT VENTRICLE EJECTION FRACTION BY 8%.”

 

 

The hallmark of drug eluting stents (DES) is the reduction of restenosis, which is achieved by anti-proliferative drugs that elute from a polymer covering the struts of the DES (neo-intimal hyperplasia being significantly reduced). But first generations DES were associated with increased risk of stent thrombosis (ST) as compared to bare-metal stents (BMS), because of strut size and the inflammation/hypersensitivity triggered by the polymer. Late ST sparked off interest in development of DES with biodegradable polymers (BP) to improve safety profile. A pooled analysis of the ISAR-TEST 3, ISAR-TEST 4 and LEADERS trials found that BP-DES were associated with significantly reduced ST and clinically driven target lesion revascularization (TLR) at the end of 4 years (Eur Heart J 2012; 33:1214-22).

Continue reading “BIODEGRADABLE POLYMER DRUG ELUTING STENTS.”

 

 

A recent paper addressing etiology of sudden death in sports has been published by JACC (2016;67:2018-15) against the background that accurate knowledge of sudden cardiac death (SCD) in athletes and its precipitating factors is necessary to establish preventive strategies. Data is provided from a United Kingdom regional registry. The study investigated causes of SCD and their association with intense physical activity in a large cohort of athletes. The study includes 357 consecutive cases (mean age 29 years, males 92%, Caucasian 76%, competitive 69%), who underwent detailed post-mortem evaluation, including histological analysis by an expert cardiac pathologist.

Continue reading “SUDDEN DEATH IN YOUNG ATHLETES”

 

The derision and hostility of the audience was palpable, when in a recent cardiology conference in Delhi, I stated that substantial data published in the leading medical journals of the world not only exaggerated drug effects but could also be considered misleading. There was stunned silence when I mentioned the New England Journal of Medicine (NEJM) as one of the leading culprits publishing manipulated data because the NEJM is considered by most as the holy grail of medical journals.

Continue reading “THE BUSINESS OF INDUSTRY-SPONSORED PUBLICATION IN MEDICAL JOURNALS”

 

 

The Takotsubo syndrome (TTS) is an acute heart failure syndrome that largely affects post-menopausal women. It was (first) described by the Japanese in 1990; the disease is defined by transient systolic and diastolic left ventricle dysfunction accompanied by a range of wall motion abnormalities. It predominantly affects elderly women and is usually preceded an emotional or physical trigger. It is accompanied by substantially increased morbidity and mortality that equal those of acute coronary syndrome (ACS). The clinical presentation in the acute phase consisting of electrocardiographic findings and biomarker profiles are not dissimilar from ACS. In fact 1% to 2% of suspect6ed patients of ACS are actually suffering from TTS. Both TTS and ACS have many common clinical features at admission.

Continue reading “THE TAKOTSUBO ( BROKEN HEART ) SYNDROME”

 

 

More than a 5 years ago the EPHESUS trial found that eplerenone (administered orally 25 to 50 mg a day) cut mortality significantly in 30 days post-randomization in patients with acute myocardial infarction (MI). Eplerenone had been known to reduce mortality in patients with heart failure (HF) or diabetes when begun early after myocardial infarction. All international guidelines have therefore accorded it a Class I indication. Eplerenone’s benefits were greatest when given early (3 to 7 days) post- myocardial infarction and are independent of standard care such as reperfusion, angiotensin converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, statin, or diuretics. Crucially, eplerenone has been found to reduce mortality by lowering sudden cardiac death and therefore would be an important component in immediate post-MI treatment, when automatic implantable carioverter-defibrillators are not advised.

Continue reading “EPLERENONE FOR ACUTE MYOCARDIAL INFARCTION”

 

For more than 50 years we were made to believe that vegetable oils, because they lowered cholesterol and low-density lipoprotein (LDL), were better for cardiovascular health than saturated fats present in meat and cheese. It is still widely accepted that diets rich in polyunsaturated fats protect against heart disease. In fact the Global Burden of Disease team reported that reduced intake of omega-5 polyunsaturated fats, the most commonly consumed polyunsaturated fats, leads to 700,000 deaths from coronary heart disease.

Continue reading “VEGETABLE OILS WITH 6-OMEGA FAT COULD BE DANGEROUS.”

 

The STICH trial, published 5 years ago, randomly assigned 1212 patients with an ejection fraction of less than 35% and coronary disease amenable to coronary-artery bypass grafting (CABG) to receive optimal medical therapy for heart failure and coronary artery disease (602 patients) or to receive optimal medical therapy and CABG. There was, after 5 years of follow up, no significant difference in death from any cause. Surprisingly, in a sub-study, assessment of myocardial viability failed to show any patient that may have benefited from CABG. No patient had >50% left main coronary artery  stenosis or Canadian Cardiovascular Society class III-IV angina.

Continue reading “CABG FOR PATIENTS WITH POOR LEFT VENTRICLE FUNCTION- STICHES STUDY”

Having never set eyes on the land he was called to partition

Between two people fanatically at odds,

With their different diets and incompatible gods.

He got down to work, to the task of settling the fate

of millions.

Continue reading “FROM MR. JINNAH THEN TO BRUSSELS TODAY”

 

 

The FDA approved alirocumab (Praluent), the first monoclonal antibody to inhibit a protein called PCSK9 that was discovered a decade back. Cholesterol is cleared by receptors in the liver and these receptors are degraded by PCSK9. So if you block PCSK9, the cholesterol clearing receptors remain intact and active, pulling down cholesterol levels from the body.

Continue reading “PCSK9 INHIBITORS MADE SIMPLE.”